Latest Intelligence in United States

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
Expert View
Expert View

Xigris: struggling to overcome its problems

The once lauded drug Xigris is struggling to recover from a series of setbacks, despite existing in a potentially lucrative market with little competition. After disappointing US sales, Xigris has now been launched in Europe. Datamonitor's Michael Randle asks if Eli Lilly can take advantage of its status as the only approved severe sepsis treatment and breathe new life into its sleeping giant.

Published By Datamonitor
15 Nov 2002
Expert View
Expert View

Xigris: Lilly's sepsis flop misses out

Eli Lilly's Xigris sales have proved disappointing, for the year-to-date period ending February 28 2002 sales reached just $14 million, bringing total sales to $35 million since the drug's launch in late November 2001. Industry analysts had predicted sales of between $300 and $500 million in 2002, but this now seems unrealistic, so where did it all go wrong?

Published By Datamonitor
22 Mar 2002
CommentWire
CommentWire

Xenova/QLT: tackling multidrug resistance

UK biotech Xenova and its North American ally QLT will trial tariquidar for multidrug resistance in non-small cell lung cancer. As long as the results are positive, tariquidar should have a bright future: multidrug resistance is an increasingly serious problem in cancer treatment, and the developers look set to provide strong marketing support.

Published By Datamonitor
11 Jul 2002
CommentWire
CommentWire

Xanthus: more hurdles to clear for Symadex

Xanthus Life Sciences has begun dosing patients in a phase II trial of Symadex in recurrent colorectal cancer. While this is clearly a positive step in Symandex' development, the drug candidate still has phase III trials to contend with and, even if Symandex proves fit for launch here, Xanthus will need to find a marketing partner to help it achieve commercial success in the tough cancer market.

Published By Datamonitor
17 Jan 2006
CommentWire
CommentWire

Xanthus Pharmaceuticals: trial hopes to meet unmet need in secondary leukemia

Xanthus Pharmaceuticals has begun patient dosing in a Phase III trial of its drug Xanafide. Patients with secondary acute myeloid leukemia are poorly served by existing drug therapy; physicians are therefore likely to be enthusiastic about a drug which can improve treatment outcomes. At this stage of development, however, it is too early to forecast the chances of Xanthus's drug being successful.

Published By Datamonitor
10 Oct 2007
CommentWire
CommentWire

Wyeth: yet more bad news for Pristiq

The termination of Pristiq for fibromyalgia represents another setback for Wyeth, which had high hopes for its follow-on drug to Effexor. However, all is not lost as Wyeth's greatest commercial opportunity for Pristiq will be gained through indications for depression and menopausal symptoms, although heart and liver safety concerns added to regulatory delays may still limit the drug's potential.

Published By Datamonitor
10 Aug 2007
CommentWire
CommentWire

Wyeth: WHI Premarin study stops early

The 2002 halt of the WHI study using Wyeth's [WYE] Prempro triggered heavy losses to Premarin family sales. Now the remaining study, including Premarin itself, has also come to an abrupt end due an increased risk of stroke. After losing around $1 billion of the brand's annual revenue since 2002, this slide is now unlikely to slow.

Published By Datamonitor
05 Mar 2004
CommentWire
CommentWire

Wyeth: Prempro linked with dementia

A recent study published in the Journal of the American Medical Association has shown that Wyeth's hormone combination therapy Prempro increases the risk of probable dementia in postmenopausal women aged 65 years or older. Further studies are needed to establish the role of estrogen therapies in the onset of Alzheimer's disease.

Published By Datamonitor
29 May 2003
CommentWire
CommentWire

Wyeth: positive Aprela results bode well for planned portfolio strategy

Wyeth has announced new positive Phase III data for its menopause treatment Aprela. The potential blockbuster is well positioned to provide a unique approach to the treatment of menopausal symptoms in women at risk of developing osteoporosis, and assuming regulatory hurdles can be overcome, Aprela will help further maintain Wyeth's position as a leading women's health player.

Published By Datamonitor
29 Jul 2009
CommentWire
CommentWire

Wyeth: optimizing bazedoxifene's lifecycle strategy

Wyeth has received an approvable letter from the FDA which confirms that bazedoxifene, to be marketed as Viviant, is likely to be indicated for the prevention of postmenopausal osteoporosis. This is the first step in what Datamonitor expects to be a successful and maintained brand lifecycle management strategy.

Published By Datamonitor
25 Apr 2007

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.